Home

Project Z2

Integrated information platform and cross-project biostatistical analyses

Principal Investigator: Prof. Dr. Meinhard Kieser


PELICAN

 

Short Summary

The two objectives of the proposed project are (i) to integrate the biomedical data of the various SFB/TRR77 research projects into a common information platform and (ii) to provide participating project groups with biostatistical tools and consultancy as well as to carry out cross-project analyses. The integration of tissue, molecular, genetic and clinical data into a common platform enables data sustainability and comprehensive analyses. The integrated analyses meet the challenge of the multidisciplinarity of clinical and genetic research by combining data arising from various research projects of the SFB/TRR77.

 

List of relevant publications

  1. Buck J, Garde S, Kohl CD, Knaup P (2009) Towards a comprehensive electronic patient record to support an innovative individual care concept for premature infants using the openEHR approach. Int J Med Inf 78(8):521-531.
  2. Dai L, Gast A, Horska A, Schrappe M, Bartram CR, Hemminki K, Kumar R, Lorenzo Bermejo J (2009) A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer In press.
  3. Dünnebier T, Lorenzo Bermejo J, Haas S, Fischer HP, Pierl CB, Justenhoven C, Brauch H, Baisch C, Gilbert M, Harth V, Pesch B, Brüning T, Ko YD, Hamann U (2009) Common Variants in the UBC9 Gene encoding the SUMO-Conjugating Enzyme are associated with Breast Tumor Grade. Int J Cancer In press.
  4. Hemminki K, Lorenzo Bermejo J (2009) Family History of Prostate Cancer During Rapidly Increasing Incidence. New York Humana Press.
  5. Knaup-Gregori P, Ecker M, Albashiti F, Spitalewsky K, Dickhaus H (2009) Individualisierte Gesundheitsportale als zentrale IT-Komponenten für Ambient Assisted Living: Motivation und Anforderungen.  Ambient Assisted Living 2 Deutscher AAL-Kongress mit Ausstellung Technologien – Anwendungen 27-28 Januar 2009 in Berlin Tagungsbandbeiträge Berlin: VDE-Verlag.
  6. Lorenzo Bermejo J, Fischer C, Schulz A, Cremer N, Hein F, Beckmann L, Chang-Claude J, Hemminki K (2009) Representation of genetic association via attributable familial relative risks in order to identify polymorphisms functionally relevant to rheumatoid arthritis. BMC Proceedings 3:Suppl7, S.10.
  7. Lorenzo Bermejo J, Sundquist J, Hemminki K (2009) Sex-specific familial risks of urinary bladder cancer and associated neoplasms in Sweden. Int J Cancer 124:2166-71.
  8. Pechlivanis S, Lorenzo Bermejo J, Pardini B, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Forsti A (2009) Genetic variation in adipokine genes and risk of  colorectal cancer. Eur J Endocrinol in press.
  9. Hemminki K, Forsti A, Lorenzo Bermejo J (2008) Etiologic impact of known cancer susceptibility genes. Mutat Res 658:42-54.
  10. Hemminki K, Lenner P, Sundquist J, Lorenzo Bermejo J (2008) Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 26:1850-57.
  11. Hemminki K, Sundquist J, Lorenzo Bermejo J (2008) Familial risks for cancer as the basis for evidence-based clinical referral and counseling. Oncologist 13(3):239-47.
  12. Hemminki K, Sundquist J, Lorenzo Bermejo J (2008) How common is familial cancer? Ann Oncol 19:163-67.
  13. Krockenberger K, Luntz SP, Knaup P (2008) Usage and usability of standard operating procedures (SOPs) among the coordination centers for clinical trials (KKS). Methods Inf Med 47:505-10.
  14. Lorenzo Bermejo J (2008) Gene-environment interactions and familial relative risks. Hum Hered 66:170-79.
  15. Lorenzo Bermejo J, Sundquist J, Hemminki K (2008) Effect of parental history of cancer on the development of second neoplasms after lymphoma at the same site than the parents. Leukemia 22:879-80.
  16. Bloethner S, Snellman E, Lorenzo Bermejo J, Hiripi E, Gast A, Thirumaran RK, Wellenreuther R, Hemminki K, Kumar R (2007) Differential gene expression in melanocytic nevi with the V600E BRAF mutation. Genes Chromosom Cancer 46:1019-27.
  17. Garde S, Fraser JE, Nematpoor N, Pollex R, Morin C, Forte A, Rabbani S, Panchal C, Gupta MB (2007) Cloning, expression, purification and functional characterization of recombinant human PSP94. Protein Expr Purif 54:193-203.
  18. Garde S, Hovenga E, Buck J, Knaup P (2007) Expressing clinical data sets with openEHR archetypes: A solid basis for ubiquitous computing. Int J Med Inform 76 Suppl 3:S334-41.
  19. Garde S, Knaup P, Hovenga E, Heard S (2007) Towards semantic interoperability for electronic health records. Methods Inf Med 46:332-43.
  20. Knaup P, Garde S, Haux R (2007) Systematic planning of patient records for cooperative care and multicenter research. Int J Med Inform 76:109-17.
  21. Lorenzo Bermejo J, Sundquist J, Hemminki K (2007) Risk of cancer among the offspring of women who experienced parental death during pregnancy. Cancer Epidemiol Biomarkers Prev 16:2204-06.
  22. Pechlivanis S, Pardini B, Lorenzo Bermejo J, Wagner K, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Forsti A (2007) Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer 14:733-40.
  23. Friede T, Kieser M (2006) Sample size recalculation in internal pilot study designs: a review. Biometrical Journal 48:537-55.
  24. Garde S, Knaup P (2006) Requirements Engineering in Health Care: The Example of Chemotherapy-Planning in Paediatric Oncology. Requirements Engineering Journal 11:265-78.
  25. Hemminki K, Granström C, Sundquist J, Lorenzo Bermejo J (2006) The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Hered Cancer Clin Pract 4:85-96.
  26. Hemminki K, Lorenzo Bermejo J, Forsti A (2006) The balance between heritable and environmental aetiology of human disease. Nat Rev Genet 7:958-65.
  27. Kieser M (2005) A note on adaptive modification of hypotheses in flexible designs. Drug Information Journal 39:215-22.
  28. Knaup P, Garde S, Merzweiler A, Graf N, Schilling F, Weber R, Haux R (2005) Towards shared patient records: An architecture for using routine data for nationwide research. Int J Med Inform 75:191-200.
  29. Lorenzo Bermejo J, Eng C, Hemminki K (2005) Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology 129:1889-99.
  30. Lorenzo Bermejo J, Hemminki K (2005) Familial risk of cancer shortly after diagnosis of the first familial tumor. J Natl Cancer Inst 97:1575-79.
  31. Merzweiler A, Weber R, Garde S, Haux R, Knaup-Gregori P (2005) TERMTrial-terminology-based documentation systems for cooperative clinical trials. Comput Methods Programs Biomed 78:11-24.
  32. Wüst K, Kieser M (2005) Including long- and short-term data in blinded sample size recalculation for binary endpoints. Computational Statistics & Data Analysis 48:835-55.
  33. Wüst K, Kieser M (2005) Monitoring continuous long-term outcomes in adaptive designs. Communications in Statistics Computation and Simulation 34:321-41.
  34. Friede T, Kieser M (2004) Sample size recalculation for binary data in internal pilot study designs. Pharmaceutical Statistics 3:269-79.
  35. Garde S, Baumgarten B, Basu O, Graf N, Haux R, Herold R, Kutscha U, Schilling F, Selle B, Spiess C, Wetter T, Knaup P (2004) A meta-model of chemotherapy planning in the multi-hospital/multi-trial-center-environment of pediatric oncology. Methods Inf Med 43:171-83.
  36. Lorenzo Bermejo J, Garcia Perez A, Hemminki K (2004) Contribution of the defective BRCA1, BRCA2 and CHEK2 genes to the familial aggregation of breast cancer. Hered Cancer Clin Pract 2:185-91.
  37. Friede T, Kieser M, Neuhäuser M, Böning H (2003) A comparison of procedures for adaptive choice of location tests in flexible two-stage designs. Biometrical Journal 45:292-310.
  38. Friede T, Kieser M (2003) Blinded sample size reassessment in non-inferiority and equivalence trials. Statistics in Medicine 22:995-1007.
  39. Kieser M, Friede T (2003) Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Statistics in Medicine 22:3571-81.
  40. Wüst K, Kieser M (2003) Blinded sample size recalculation for normally distributed outcomes using long- and short-term data. Biometrical Journal 45:915-30.
  41. Friede T, Kieser M (2002) On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation. Statistics in Medicine 21:165-76.
  42. Kieser M, Schneider B, Friede T (2002) A bootstrap procedure for adaptive selection of the test statistic in flexible two-stage designs. Biometrical Journal 44:641-52.
  43. Knaup P, Wiedemann T, Bachert A, Creutzig U, Haux R, Schilling F (2002) Efficiency and Safety of Chemotherapy Plans for Children. CATIPO - a nationwide approach. Artif Intell Med 24:229-42.
  44. Merzweiler A, Ehlerding H, Creutzig U, Graf N, Hero B, Kaatsch P, Zimmermann M, Weber R, Knaup P (2002) Terminologiestandardisierung in der Pädiatrischen Onkologie - der Basisdatensatz. Klin Padiatr 214:212-17.
  45. Friede T, Kieser M (2001) Sample size adjustment in clinical trials for proving equivalence. Drug Information Journal 35:1401-08.
  46. Friede T, Kieser M (2001) A comparison of methods for adaptive sample size adjustment. Statistics in Medicine 20:3861-73.
  47. Friede T, Kieser M (2001) A loss-function based approach for dose-response trials with adaptive two-stage designs. Journal of Epidemiology and Biostatistics 6:317-24.

 

 

Impressum          © SFB/TRR77 Livercancer        Webdesign: ki-werkstatt, Karlsruhe.